Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of March 2003

Biacore International AB (publ)

C/o Biacore International SA
Puits-Godet 12
CH-2000 Neuchatel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F  X
Form 40-F

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.

No   X

If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b):


Uppsala, Sweden, 12th March 2003

Biacore International AB (SSE and NASDAQ:BCOR) today announced a major new
innovation for accelerating research in functional proteomics.  Biacore(r)3000
is the highest performance SPR-based research system available today for
studying biomolecular interactions. This has now been made more powerful
through the incorporation of automated and increased capacity recovery
functionality and direct MALDI target deposition for further analysis by
MALDI-TOF, or even TOF/TOF mass spectrometry.

This new automated SPR-MS functionality for Biacore(r)3000 has been developed by
Biacore as part of its ongoing collaboration with Bruker Daltonics Inc (NASDAQ:
BDAL) to jointly create a comprehensive technology solution for functional
proteomics studies.

The SPR technology of Biacore(r)3000 provides the means of detecting, capturing
and delivering valuable protein without any labeling or modification. Subsequent
sequencing by mass spectrometry is facilitated by automated sample preparation
including an option to deposit sample direct onto the MALDI plate. This means
that researchers now have ready access to critical functional SPR data on
protein-protein or protein-peptide interactions, combined directly with mass
spectrometric identification and characterization of novel proteins. This
offers researchers a new proteomics research methodology delivering a greater
understanding of the interactions underlying biological processes, critical to
the elucidation of disease processes.

The enhanced Biacore(r)3000 functionality has been field tested as part of
collaborations in this field with laboratories in a number of key organisations
worldwide. These include Wyeth Pharmaceuticals Inc (USA), Ludwig Institute for
Cancer Research (Melbourne Branch, Australia), University of Southern Denmark,
Odense University (Denmark) and the Integrated Proteomics System Project (Tokyo
University, Japan).

Dr. Detlev Suckau, Head of MALDI applications development at Bruker Daltonics,
said, "This new automated functionality enabling even TOF/TOF MS/MS
characterisation following recovery from SPR makes the Biacore(r)3000 in
combination with our UltraflexTOF/TOF system probably the most information-rich
technology solution for interaction proteomics a researcher can buy today."

"Biacore(r)3000 is already recognized by the world's leading research
laboratories as a powerful tool offering functional, data-rich information
providing greater insights into physiological and disease processes," commented
Clive Seymour, Vice President and Head of Biacore's Life Science Research
Business Unit. "Our advanced micro fluidics and unique chip based chemistry
delivering the highest sensitivity and high quality kinetics is now combined
with automated SPR-MS capabilities offering researchers a real opportunity to
accelerate elucidation of the Proteome."

Cautionary Statement

This press release contains certain forward-looking statements within the
meaning of the United States Private Securities Litigation Reform Act of 1995,
which, by their nature, involve risk and uncertainty because they relate to
events and depend on circumstances that will occur in the future. There are a
number of factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements.

About Biacore

Biacore is a global market leader in Surface Plasmon Resonance (SPR) technology
based systems with its own sales operations in the U.S., across Europe, Japan,
Australia and New Zealand. A strong patent portfolio protects Biacore's SPR
technology, which gives unique real-time insights into biomolecular
interactions. Target groups for the Company's products consist primarily of
medical and life science research laboratories and pharmaceutical and
biotechnology companies around the world. Biacore is focusing on drug discovery
and development as its prime areas for future growth. The Company currently has
seven systems on the market, the most important of which are:  Biacore(r)S51
for applications downstream of high-throughput screening (HTS) including rapid
characterization of HTS hits, and the comprehensive pre-clinical evaluation of
lead compounds, and Biacore(r)3000, which offers flexibility in key life science
research and drug discovery applications upstream of HTS. The recently
introduced Biacore(r)C is specifically designed for compliant concentration
analysis of biopharmaceuticals in GLP/GMP applications. A new SPR array chip
system, which will provide higher information content, is expected to reach the
market in 2004.

Based in Uppsala, Sweden, the Company is listed on Stockholmsborsen and Nasdaq
in the U.S. In 2002 the Company had sales of SEK 614.2 million and an operating
income of SEK 140.6 million.

For further information, please contact:
Clive Seymour, Vice President & Head of Life Science Research Business Unit,
Biacore AB, Tel: +64 21 640 801

Scientific/Trade Press Enquiries:
Sarah Perceval, HCC.De Facto Group
+44 (0) 207 496 3300

Further information on Biacore can be found on the web:


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Biacore International AB (publ)
By: Lars-Olov Forslund
Name: Lars-Olov Forslund
Title: Chief Financial Officer
Dated: April 8, 2003